You are here:
NICE
NICE Guidance
Conditions and diseases
Cancer
Breast cancer
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
Technology appraisal guidance
Reference number:
TA263
Published:
22 August 2012
Guidance
Tools and resources
Information for the public
History
Download guidance (PDF)
Overview
1 Guidance
2 The technology
3 The manufacturer's submission
4 Consideration of the evidence
5 Implementation
6 Recommendations for further research
7 Related NICE guidance
8 Review of guidance
Appendix A: Appraisal Committee members and NICE project team
Appendix B: Sources of evidence considered by the Committee
Changes after publication
About this guidance
Changes after publication
February 2014:
minor maintenance
Next page
About this guidance
Previous page
Appendix B: Sources of evidence considered by the Committee